ROS1 Fusion Subtype Shapes Survival in Advanced Lung Cancer, Real-World Data Show
A real-world study of 55 patients with advanced ROS1-rearranged non-small cell lung cancer shows that fusion subtype, PD-L1 expression and ...
A real-world study of 55 patients with advanced ROS1-rearranged non-small cell lung cancer shows that fusion subtype, PD-L1 expression and ...
A new clinical case report shows that the oral HER2 inhibitor lapatinib, with its short half-life and low cardiac toxicity, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine